AbstractObjective To compare the dosimetry and efficacy of intracavitary brachytherapy (ICBT) and intracavitary/interstitial brachytherapy (IC+ISBT) based on CT image guidance in the treatment of stage ⅢB cervical cancer. Methods Clinical data of 93 patients with stage ⅢB cervical cancer treated in Department of Radiotherapy of Jilin Cancer Hospital from June 2014 to February 2017 were analyzed retrospectively. According to the results ofGynecological examination and pelvic MRI before brachytherapy, confirming the size of residual tumor and the degree of parauterine infiltration, all patients were divided into the ICBT and IC+ISBT groups. The D90%, D100%, V100% and D2cm3 of bladder and rectum were compared, and the short-term and long-term efficacy was observed between two groups. Results The median follow-up time was 60 months. The 5-year local control rate, distant metastasis-free survival rate and overall survival rate of all patients were 83%, 71% and 68%, respectively. Compared with the ICBT group, HR-CTV D90% in the IC+ISBT group was all more than 85Gy, while there was no significant difference between two groups (P=0.188). The D2cm3 of bladder and rectum in the IC+ISBT group was significantly decreased by 7Gy and 8Gy (both P<0.01), and the distant metastasis-free survival rate was significantly improved (P=0.009). The 5-year local control rate in the HR-CTV volume>60cm3 in the IC+ISBT group was significantly higher than that in the IC group (P=0.029). Conclusion For patients with ⅢB cervical cancer, IC+ISBT can not only ensure target coverage, but also significantly reduce the incidence of distant metastasis and the dose of organs at risk, and significantly improve the local control rate of large tumors.
Fund:Innovation Capacity Building Foundation of Jilin Province (2021C043-8)
Corresponding Authors:
Sun Baosheng, Email:xiuyuxiong@163.com
Cite this article:
Xiu Yuting,Meng Fanxu,Wang Zhuo et al. Analysis of dosimetry and clinical efficacy of intracavitary/interstitial brachytherapy in ⅢB cervical cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(6): 539-543.
Xiu Yuting,Meng Fanxu,Wang Zhuo et al. Analysis of dosimetry and clinical efficacy of intracavitary/interstitial brachytherapy in ⅢB cervical cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(6): 539-543.
[1] Tanderup K, Eifel PJ, Yashar CM, et al. Curative radiation therapy for locally advanced cervical cancer:brachytherapy is NOT optional[J]. Int J Radiat Oncol Biol Phys, 2014, 88(3):537-539. DOI:10.1016/j.ijrobp.2013.11.011. [2] Fokdal L, Sturdza A, Mazeron R, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer:analysis from the retroEMBRACE study[J]. Radiother Oncol, 2016, 120(3):434-440. DOI:10.1016/j.radonc.2016.03.020. [3] Haie-Meder C, Pötter R, Van Limbergen E, et al. Recommendations fromGynaecological (GYN) GEC-ESTRO working group (I):concepts and terms in 3D image based 3Dtreatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J]. Radiother Oncol, 2005, 74(3):235-245. DOI:10.1016/j.radonc.2004.12.015. [4] Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations fromGynaecological (GYN) GEC ESTRO working group (Ⅱ):concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology[J]. Radiother Oncol, 2006, 78(1):67-77. DOI:10.1016/j.radonc.2005.11.014. [5] Prescribing, recording, and reporting brachytherapy for cancer of the cervix[J]. J ICRU, 2013, 13(1-2):NP. DOI:10.1093/jicru/ndw027. [6] Kuipers T, Hoekstra CJ, Riet AV, et al. HDR brachytherapy applied to cervical carcinoma with moderate lateral expansion:modified principles of treatment[J]. Radiother Oncol, 2001, 58(1):25-30. DOI:10.1016/s0167-8140(00)00320-0. [7] Kirisits C, Lang S, Dimopoulos J, et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:design, application, treatment planning, and dosimetric results[J]. Int J Radiat Oncol Biol Phys, 2006, 65(2):624-630. DOI:10.1016/j.ijrobp.2006.01.036. [8] Fokdal L, Tanderup K, Hokland SB, et al. Clinical feasibility of combined intracavitary/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem/ring applicator in situ and virtual preplanning of the interstitial component[J]. Radiother Oncol, 2013, 107(1):63-68. DOI:10.1016/j.radonc.2013.01.010. [9] Dimopoulos JC, Lang S, Kirisits C, et al. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2009, 75(1):56-63. DOI:10.1016/j.ijrobp.2008.10.033. [10] Castelnau-Marchand P, Chargari C, Maroun P, et al. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer[J].Gynecol Oncol, 2015, 139(2):288-294. DOI:10.1016/j.ygyno.2015.09.008. [11] Tanderup K, Fokdal LU, Sturdza A, et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer[J]. Radiother Oncol, 2016, 120(3):441-446. DOI:10.1016/j.radonc.2016.05.014. [12] Mohamed S, Kallehauge J, Fokdal L, et al. Parametrial boosting in locally advanced cervical cancer:combined intracavitary/interstitial brachytherapy vs. intracavitary brachytherapy plus external beam radiotherapy[J]. Brachytherapy, 2015, 14(1):23-28. DOI:10.1016/j.brachy.2014.09.010. [13] Fenkell L, Assenholt M, Nielsen SK, et al. Parametrial boost using midline shielding results in an unpredictable dose to tumor and organs at risk in combined external beam radiotherapy and brachytherapy for locally advanced cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 79(5):1572-1579. DOI:10.1016/j.ijrobp.2010.05.031. [14] Fokdal L, Sturdza A, Mazeron R, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer:analysis from the retroEMBRACE study[J]. Radiother Oncol, 2016, 120(3):434-440. DOI:10.1016/j.radonc.2016.03.020. [15] Dang YZ, Li P, Li JP, et al. The efficacy and late toxicities of computed tomography-based brachytherapy with intracavitary and interstitial technique in advanced cervical cancer[J]. J Cancer, 2018, 9(9):1635-1641. DOI:10.7150/jca.23974. [16] 张宁,赵志鹏,程光惠,等. 局部晚期宫颈癌腔内联合组织间插植3D-1GBT的剂量学研究[J].中华放射肿瘤学杂志, 2015, 24(3):267-270. DOI:10.3760/cma.j.issn.1004-4221.2015.03.009. Zhang N, Zhao ZP, Cheng GH, et al. Dosimetric study of three-dimensional image-quided brachytherapy combined with intracavitary/interstitial brachytherapy in locally advanced cervical cancer[J]. Chin J RadiatOncol, 2015, 24(3):267-270. DOI:10.3760/cma.j.issn.1004-4221. 2015.03.009. [17] Spampinato S, Fokdal LU, Pötter R, et al. Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer:an EMBRACE analysis[J]. Radiother Oncol, 2021, 158:312-320. DOI:10.1016/j.radonc.2021.01.019. [18] Mazeron R, Maroun P, Castelnau-Marchand P, et al. Pulsed-dose rate image-guided adaptive brachytherapy in cervical cancer:dose-volume effect relationships for the rectum and bladder[J]. Radiother Oncol, 2015, 116(2):226-232. DOI:10.1016/j.radonc.2015.06.027.
2022, Vol. 31 
